News & Press: Latest News

MDMA Announces Paul LaViolette as New Chairman

Wednesday, May 11, 2016  
Share |

MDMA Announces Paul LaViolette as New Chairman


WASHINGTON, DC – The Medical Device Manufacturers Association (MDMA) announced today that industry veteran Paul LaViolette was elected as the new Chairman of the MDMA Board of Directors during the 2016 Annual Meeting.


“There is no question that medical technology innovators face unique challenges to address the pressing needs facing the health care delivery system, and MDMA will once again be the lead voice to confront them all,” said LaViolette.  “The passion and tenacity that has led to so many groundbreaking and life-changing innovations in our field are what will drive us to continue delivering the cures and therapies that patients throughout the world urgently need.”    


LaViolette highlighted the need to bridge the gap between the regulatory process and securing reimbursement, successful conclusion of MDUFA negotiations and making the two-year suspension of the medical device tax permanent as his top priorities during his chairmanship.


“Despite the headwinds that have confronted this dynamic industry over the years, we continue to see cutting-edge advancements in patient care and innovation,” said Mark Leahey, President and CEO of MDMA.  “Paul knows firsthand the countless issues facing all sizes of medical technology innovators, and his leadership will help ensure we can align the regulatory and reimbursement frameworks, and once and for all put a permanent end to the medical device tax.” 


LaViolette follows the successful two-year tenure of Scott Huennekens, President and CEO of Verb Surgical Inc.  LaViolette currently serves as the Chairman of several medical technology boards including CardioFocus, Direct Flow Medical, TransEnterix and Ximedica.  He brings over 30 years of global medical technology marketing and general management experience, including as Chief Operating Officer at Boston Scientific Corporation.  He also serves as the Managing Partner & Chief Operating Officer of SV Life Sciences.


The MDMA Board of Directors also added two new members to the board.  They are:

  • Jason Richey, President of Neuromodulation, LivaNova PLC
  • Brian Webster, President and CEO, Physio Control, Inc.

The selections were made during another successful MDMA Annual Meeting where nearly 200 medical technology executives heard from Dean Kamen, Senior Adviser to the President Valerie Jarrett, FDA Commissioner Robert Califf, CDRH Director Jeff Shuren, CMS' Director of the Center for Clinical Standards and Quality Kate Goodrich and many more.